• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Rhythm Pharmaceuticals, Inc. - Common Stock (NQ:RYTM)

    94.14 +0.73 (+0.78%)
    Delayed Quote Updated: 9:38 AM EDT, Oct 2, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 11,926
    Open 94.97
    Bid (Size) 93.67 (100)
    Ask (Size) 94.61 (100)
    Prev. Close 93.41
    Today's Range 93.69 - 95.31
    52wk Range 74.50 - 122.20
    Shares Outstanding 66,684,077
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Rhythm Pharmaceuticals Announces Health Canada Approval of IMCIVREE® (setmelanotide) for Weight Management in Adult and Pediatric Patients 4 years of Age and Older with Acquired Hypothalamic Obesity
    -- First targeted therapy approved in Canada for patients four years and older living with acquired hypothalamic obesity (HO) -- 
    From Rhythm Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Rhythm Pharmaceuticals Announces New Data Presentations at the European Society for Paediatric Endocrinology Meeting
    From Rhythm Pharmaceuticals, Inc.
    Via GlobeNewswire

    Performance

    YTD
    -10.4%
    -10.4%
    1 Month
    -10.1%
    -10.1%
    3 Month
    -17.5%
    -17.5%
    6 Month
    +9.1%
    +9.1%
    1 Year
    -5.9%
    -5.9%

    More News

    Read More
    News headline image
    Here’s How Much You Would Have Made Owning Rhythm Pharmaceuticals Stock In The Last 5 Years ↗
    Via Benzinga
    News headline image
    Here's How Much $100 Invested In Rhythm Pharmaceuticals 5 Years Ago Would Be Worth Today ↗
    Via Benzinga
    News headline image
    Billionaire Stanley Druckenmiller Is Quietly Loading Up on Healthcare Stocks -- Here's What His New Positions Reveal ↗
    Via The Motley Fool
    News headline image
    Rhythm Pharmaceuticals Announces MHLW Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity (HO) in Japan
    From Rhythm Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Eli Lilly and Novo Nordisk Can't Treat This Form of Obesity. Billionaire Stanley Druckenmiller Is Betting Rhythm Pharmaceuticals Can ↗
    Via The Motley Fool
    News headline image
    Rhythm Pharmaceuticals Announces Appointment of Manher (AJ) Joshi as Chief Medical Officer
    From Rhythm Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Rhythm Pharmaceuticals Eyes AHO Growth, Global IMCIVREE Expansion and Pipeline Catalysts ↗
    Via MarketBeat
    News headline image
    Rhythm Pharmaceuticals (RYTM) Q2 2026 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings
    News headline image
    Rhythm Pharmaceuticals Announces IMCIVREE® (setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalamic Injury or
    From Rhythm Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences
    From Rhythm Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Rhythm Pharmaceuticals Q2 Earnings Call Highlights ↗
    Via MarketBeat
    Topics Earnings
    News headline image
    Full Transcript: Rhythm Pharmaceuticals Q2 2026 Earnings Call ↗
    Via Benzinga
    Topics Earnings
    News headline image
    Rhythm Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update
    From Rhythm Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Rhythm Pharmaceuticals Announces Preliminary Data from Phase 2 Trial that Showed RM-718 Demonstrated Positive Efficacy Signal in Acquired Hypothalamic Obesity
    From Rhythm Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Rhythm Pharmaceuticals to Report Second Quarter 2026 Financial Results on Tuesday, August 4, 2026
    From Rhythm Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Rhythm Pharmaceuticals Announces The New England Journal of Medicine Publication of Phase 3 TRANSCEND Trial Results in Acquired Hypothalamic Obesity
    From Rhythm Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Rhythm Pharmaceuticals Announces Multiple New Data Presentations from MC4R Agonists in Acquired Hypothalamic Obesity (HO), Bardet-Biedl Syndrome (BBS) and Prader-Willi Syndrome (PWS) at ENDO 2026
    From Rhythm Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026
    From Rhythm Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Rhythm Pharmaceuticals to Announce Interim Six-Month Phase 2 Results Evaluating Setmelanotide in Patients with Prader-Willi Syndrome
    From Rhythm Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Rhythm Pharmaceuticals Announces Seven Abstracts Accepted for Presentation at ENDO 2026
    From Rhythm Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Rhythm Pharmaceuticals Announces Publication of New Bardet-Biedl Syndrome Diagnostic Algorithm in the American Journal of Medical Genetics
    From Rhythm Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences
    From Rhythm Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Rhythm Pharmaceuticals Announces New Data Presentations at the 2026 European Congress of Endocrinology
    From Rhythm Pharmaceuticals, Inc.
    Via GlobeNewswire

    Frequently Asked Questions

    Is Rhythm Pharmaceuticals, Inc. - Common Stock publicly traded?
    Yes, Rhythm Pharmaceuticals, Inc. - Common Stock is publicly traded.
    What exchange does Rhythm Pharmaceuticals, Inc. - Common Stock trade on?
    Rhythm Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Rhythm Pharmaceuticals, Inc. - Common Stock?
    The ticker symbol for Rhythm Pharmaceuticals, Inc. - Common Stock is RYTM on the Nasdaq Stock Market
    What is the current price of Rhythm Pharmaceuticals, Inc. - Common Stock?
    The current price of Rhythm Pharmaceuticals, Inc. - Common Stock is 94.14
    When was Rhythm Pharmaceuticals, Inc. - Common Stock last traded?
    The last trade of Rhythm Pharmaceuticals, Inc. - Common Stock was at 10/02/26 09:38 AM ET
    What is the market capitalization of Rhythm Pharmaceuticals, Inc. - Common Stock?
    The market capitalization of Rhythm Pharmaceuticals, Inc. - Common Stock is 6.28B
    How many shares of Rhythm Pharmaceuticals, Inc. - Common Stock are outstanding?
    Rhythm Pharmaceuticals, Inc. - Common Stock has 6B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.